Revenue rose to SEK 410.7 million (7.2). The substantial increase is linked to the company's recently signed licensing agreement with Jazz Pharmaceuticals for SAN2355, which resulted in a payment of SEK 404.8 million to Saniona. This has also had a clear positive impact on other items in the income statement compared to last year's figures.
Operating profit amounted to SEK 359.9 million (-18.9), with an operating margin of 87.6 percent.
Profit before tax was SEK 358.3 million (-32.5).
Net profit after tax came in at SEK 329.6 million (-29.5), or SEK 2.35 per share (-0.26).
Cash flow from operating activities totaled SEK 371.3 million (-12.6).
Cash and cash equivalents amounted to SEK 672.8 million (41.3).
"Looking ahead, our priorities are clear: to advance our pipeline toward key clinical milestones, deepen strategic collaborations, and maintain financial discipline. We are building a focused portfolio in neurological and psychiatric diseases and leveraging partner funding to reach critical value inflection points. Our recent agreements with Acadia and Jazz confirm our strengths and our partnership-driven business model, enabling us to independently advance several internal assets through phase 2 proof-of-concept studies," commented CEO Thomas Feldthus.
| Saniona, SEK million | Q3-2025 | Q3-2024 | Change |
| Net revenue | 410.7 | 7.2 | 5,604.2% |
| Operating profit | 359.9 | -18.9 | |
| Operating margin | 87.6% | ||
| Profit before tax | 358.3 | -32.5 | |
| Net profit | 329.6 | -29.5 | |
| Earnings per share, SEK | 2.35 | -0.26 | |
| Cash flow from operating activities | 371.3 | -12.6 | |
| Cash and cash equivalents | 672.8 | 41.3 | 1,529.1% |
